Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.


We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by Reaxense.


Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.


Our top-notch dedicated system is used to design specialised libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.


Our library stands out due to several important features:


  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.

  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.

  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.

  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
Q9NZP8

UPID:
C1RL_HUMAN

ALTERNATIVE NAMES:
C1r-like serine protease analog protein

ALTERNATIVE UPACC:
Q9NZP8; Q53GX9

BACKGROUND:
Complement C1r subcomponent-like protein, identified by its alternative name C1r-like serine protease analog protein, mediates the critical process of HP/haptoglobin proteolytic cleavage in the endoplasmic reticulum. This specific activity underscores the protein's significance in proteolytic systems, which are vital for proper cellular function.

THERAPEUTIC SIGNIFICANCE:
Exploring the functionalities of Complement C1r subcomponent-like protein holds promise for unveiling novel therapeutic avenues. Given its central role in the proteolytic pathway, strategies aimed at modulating its activity could lead to breakthroughs in treating diseases where proteolytic balance is disrupted.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.